HER-2 and topo-isomerase IIalpha as predictive markers in a population of node-positive breast cancer patients randomly treated with adjuvant CMF or epirubicin plus cyclophosphamide.
about
Endocrinology and hormone therapy in breast cancer: endocrine therapy in premenopausal womenLong-term prognostic significance of HER-2/neu in untreated node-negative breast cancer depends on the method of testingCoexistence of HER2 over-expression and p53 protein accumulation is a strong prognostic molecular marker in breast cancerAssociations between clinicopathological prognostic factors and pAkt, pMAPK and topoisomerase II expression in breast cancer.The epidermal growth factor receptor family in breast cancer.Chromosome 17 centromere duplication and responsiveness to anthracycline-based neoadjuvant chemotherapy in breast cancer.Testing for HER2 in Breast Cancer: A Continuing Evolution.Topo2α protein expression predicts response to anthracycline combination neo-adjuvant chemotherapy in locally advanced primary breast cancer.Evaluation of the prognostic role of centromere 17 gain and HER2/topoisomerase II alpha gene status and protein expression in patients with breast cancer treated with anthracycline-containing adjuvant chemotherapy: pooled analysis of two Hellenic CoAlteration of topoisomerase II-alpha gene in human breast cancer: association with responsiveness to anthracycline-based chemotherapy.Assessment of Topoisomerase II α status in breast cancer by quantitative PCR, gene expression microarrays, immunohistochemistry, and fluorescence in situ hybridization.Targeted therapy in breast cancer: the HER-2/neu gene and protein.HER2 and TOP2A in high-risk early breast cancer patients treated with adjuvant epirubicin-based dose-dense sequential chemotherapy.Prognostic significance of TOP2A gene dosage in HER-2-negative breast cancerMatters of the heart: cardiac toxicity of adjuvant systemic therapy for early-stage breast cancerIron chelators with topoisomerase-inhibitory activity and their anticancer applications.Outcome of patients with early-stage breast cancer treated with doxorubicin-based adjuvant chemotherapy as a function of HER2 and TOP2A statusCardiac tolerability of concurrent administration of trastuzumab and anthracycline-based regimen as adjuvant chemotherapy for breast cancer.Efficacy of high-dose alkylating chemotherapy in HER2/neu-negative breast cancer.CK5/6, EGFR, Ki-67, cyclin D1, and nm23-H1 protein expressions as predictors of pathological complete response to neoadjuvant chemotherapy in triple-negative breast cancer patients.Genomic predictors of response to doxorubicin versus docetaxel in primary breast cancer.Randomized trial comparing cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) with rotational CMF, epirubicin and vincristine as primary chemotherapy in operable breast carcinoma.Topoisomerase expression in oral squamous cell carcinoma: relationship with cancer stem cells profiles and lymph node metastasis.Topoisomerase II alpha protein and responsiveness of breast cancer to adjuvant chemotherapy with CEF compared to CMF in the NCIC CTG randomized MA.5 adjuvant trial.Topoisomerase II alpha expression and the Ki-67 labeling index correlate with prognostic factors in estrogen receptor-positive and human epidermal growth factor type-2-negative breast cancer.
P2860
Q24797219-B8DDEA55-448E-4AF1-850E-94604423AD20Q24797752-3B291F33-DFAF-40E7-9F91-A001CC5528CAQ24803894-164CE8A2-2F54-4C81-AEEB-BC5EE2D9FEF1Q33816025-5A09F899-C9F6-4163-B89A-73C46199F93EQ34363400-261A303B-0929-4F62-8039-E2162151573CQ34417532-9B0A11D1-B0E7-4229-B17C-D23E89BAB200Q34424285-05FE42E9-4E2F-47CF-8BFE-BEEF95CF8EA1Q34433737-77193CDA-2C43-408F-9D43-66B598ADB666Q34640536-BD1C1D3E-FACD-4D69-9A8A-75BDF1BB0FA8Q34743488-E50A8866-571D-4B0A-9E2E-A926FCD2D87DQ34805496-791D8AD9-07BC-49E2-9449-D16116F89CAFQ35648508-22730D78-4036-4043-A4FF-19D600614EA9Q35744973-00AC5649-1F4F-4225-8BCB-459728223BFFQ36349584-8CEFA0D0-9FA1-4303-AB17-21EF9911C626Q36410651-4251C2CA-1B28-4C31-BB19-AA19834099F0Q36568915-C329CB1B-99DC-4352-9B7B-F5AC2608F91DQ37324977-10A0BD72-1446-4DB9-B8FF-B824A6D2E40EQ37716211-0F911415-25AB-4323-9497-851D67A47129Q39215738-CC146B36-3162-43F0-8797-9556601AB307Q42479947-C6B58CA2-FC54-4EA7-995A-53B25CDA6D7FQ42486311-C53E4E2F-F879-411D-BAB2-0207FF88DA22Q44068917-F161BE40-C5CE-4E69-AF0C-966FDE0318D0Q47657563-D110F66E-1F85-4C17-ACC3-343BE26F6BE9Q54376091-B56C6C5C-6790-4565-ACED-7048BC025F47Q54577077-F57DBE85-1C2C-4C81-8D3F-1B70CD5357C4
P2860
HER-2 and topo-isomerase IIalpha as predictive markers in a population of node-positive breast cancer patients randomly treated with adjuvant CMF or epirubicin plus cyclophosphamide.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
2001年论文
@zh
2001年论文
@zh-cn
name
HER-2 and topo-isomerase IIalp ...... rubicin plus cyclophosphamide.
@en
type
label
HER-2 and topo-isomerase IIalp ...... rubicin plus cyclophosphamide.
@en
prefLabel
HER-2 and topo-isomerase IIalp ...... rubicin plus cyclophosphamide.
@en
P2093
P356
P1433
P1476
HER-2 and topo-isomerase IIalp ...... rubicin plus cyclophosphamide.
@en
P2093
A Vindevoghel
D Gancberg
D Larsimont
J P Lobelle
P304
P356
10.1023/A:1011669223035
P577
2001-08-01T00:00:00Z